Published on January 29th, 2016 | by Recipharm0
Recipharm presents 2015 International Environmental Award winner
Recipharm is pleased to announce that its eighth International Environmental Award has been won by Jerker Fick, Docent at Department of Chemistry, Umeå University, Sweden, for his research into the environmental effects of pharmaceuticals.
Through his determined and focused work, Jerker Fick has demonstrated not only in the laboratory, but also in full-scale experiments, how pharmaceuticals impact the environment. Significantly, his research has clearly demonstrated how resistance to antibiotics can occur in close proximity to water production facilities, wastewater treatment plants, and how the residues of pharmaceutical products can disturb the natural behavior of fish.
Lars Backsell, Chairman of the Board of Recipharm, commented: “We are delighted to present this award to Jerker. Indeed, his multidisciplinary approach and the insight and mind-set to study the “cocktail” of emerging organic contaminants, and their long-time effects, makes Jerker Fick’s research an integral part on how to understand and assess the impact of pharmaceuticals on the environment.”
He continued: “Jerker’s published articles in recognised scientific papers, combined with the more “popular scientific” presentation of his work raises the awareness in both laymen and scientists of the complex issue of pharmaceuticals and their impact on the environment.”
Commenting on winning the award, Jerker Fick remarked: “I am very pleased to have secured this accolade. It is highly encouraging that a CDMO like Recipharm takes the environment so seriously and recognises the contribution that research like mine can make to drawing attention to pharmaceutical impact, as we work together to protect the environment.”
Lars Backsell, Recipharm Chairman of the Board, Tel: +46 8 602 52 00
Jerker Fick, email@example.com, +46 90 786 93 24
For media enquiries, please contact Tristan Jervis or Alex Heeley at De Facto Communications on:
Recipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 2,500 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material including API and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm’s turnover is approximately SEK 3.4 billion and the Company operates development and manufacturing facilities in Sweden, France, the UK, Germany, Spain, Italy and Portugal and is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on NASDAQ Stockholm.
For more information on Recipharm and our services, please visit www.recipharm.com
Photo: Johan Gunséus